puromycin aminonucleoside has been researched along with cilnidipine in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arisaka, N; Hayashi, M; Kasahara, H; Kodama, H; Kuroda, J; Murakami, M; Nishiyama, C; Sato, F; Souma, S; Takahashi, T; Takashima, K; Tamura, T; Tsuda, M | 1 |
1 other study(ies) available for puromycin aminonucleoside and cilnidipine
| Article | Year |
|---|---|
Renoprotective effect of the L/N-type calcium channel antagonist cilnidipine on puromycin aminonucleoside-induced nephrosis in rats.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antimetabolites, Antineoplastic; Blood Pressure; Calcium Channel Blockers; Calcium Channels, L-Type; Calcium Channels, N-Type; Creatinine; Dihydropyridines; Enalapril; Fluorescent Antibody Technique; Male; Membrane Proteins; Nephrosis; Protective Agents; Proteinuria; Puromycin Aminonucleoside; Rats; Rats, Sprague-Dawley | 2009 |